Senate Aging Committee Hearing, Poisoned Pills: The Human Cost of Dangerous Foreign Drugs

This hearing took place on June 3rd, 2026 at 3:30 PM, as part of the United States Senate Special Committee on Aging hearing, "Poisoned Pills: The Human Cost of Dangerous Foreign Drugs."

For those unfamiliar with these special committees and hearings, here is a brief background: the Senate Special Committee on Aging was first established in 1961 and made permanent in 1977. Unlike a standing committee, it holds no legislative authority of its own. Instead, it studies and investigates the issues that affect older Americans, from Medicare and Social Security to prescription drug pricing and safety, then uses those findings to shape legislation that moves through other committees. It is currently chaired by Senator Rick Scott (R-FL), with Senator Kirsten Gillibrand (D-NY) serving as Ranking Member.

For those interested in watching it in its entirety, here is the full hearing on the committee's website.

Notes and Highlights

This was the 6th hearing held by this committee, raising the total number of witnesses to 36. The four witnesses featured were Lisa Salberg, Adam Clark-Joseph, Suzanne de la Monte, and Dinesh Thakur.

Lisa Salberg is the Founder and CEO of the Hypertrophic Cardiomyopathy Association (HCMA), a patient advocacy group (PAG) that reports serving over 20,000 families living with hypertrophic cardiomyopathy. Lisa spoke about her deep and varied journey with the condition, her family's personal struggles, and her battles with generic manufacturers, insurers, and everything she has learned along the way. Her story is beyond anything most of us could understand, and yet it is so important to recount. "My insurance was not covering the name brand, forcing me to generics..." She then noted how critical her blood levels are in order to remain eligible for a transplant: "Knowing the variables, I take my very fragile veins for a lot of draws for blood, and there's a lot of expense for that as well... but when it came in at 3.9 and my levels are too low, I'm open to rejection. There are no symptoms, I'm just open to rejection."

Lisa Salberg, Founder and CEO of the HCMA, testifying before the committee.

"Sometimes you just get a bad batch." That was the note Dr. Adam Clark-Joseph recalled from his own doctor before he took matters into his own hands and started testing his pills, the work that became Valisure, the independent testing laboratory he co-founded after his personal experience with batch complications.

Dr. Adam Clark-Joseph, co-founder of Valisure, on independent testing of generic drugs.

Following Lisa and Dr. Clark-Joseph, Suzanne de la Monte recounted her experiences as a practitioner, along with her on-the-field battles and experiences with her patients. A Professor of Neuropathology, Neurology, and Neurosurgery at Brown University's Alpert Medical School whose research centers on aging-related diseases, she brought a clinician-scientist's view of how contamination and generic manufacturing reach real patients.

Dr. Suzanne de la Monte on the growing concern of adverse effects from generic drugs.

Finally, Dinesh Thakur closed out the witness testimony. Thakur is a public health activist and trained chemical engineer whose career spans drug discovery, development, clinical research, and regulatory affairs across the pharmaceutical industry. He is best known as the whistleblower whose eight-year effort exposed systemic data fraud at Ranbaxy, leading to a record-breaking $500 million settlement in 2013, the largest of its kind against a generic drug manufacturer. His story anchors Katherine Eban's Bottle of Lies. He advocates for high-quality, affordable medicines and a safe, secure drug supply chain, and is the recipient of the Joe A. Callaway Award for Civic Courage and the ACFE Cliff Robertson Sentinel Award. He runs the public-interest Thakur Foundation. His testimony included a firsthand recount of what he has seen related to drug quality, including his point that we simply do not track the consequences of poor-quality information today, that there is no liability for purchasers, and that the problems from bad generics cost roughly $18 billion a year, while testing every batch would run a tiny fraction of that.

Dinesh Thakur on scientific results recorded without proper validation.

This kind of witness testimony, further supported by articles and publications like a recent New England Journal of Medicine Perspective on substandard generic drugs as a threat to patient safety and national security, helps underscore the significance of the issue at hand.

Beyond the Witness Testimony

The hearing was chaired by Rick Scott (R-FL), joined by Ranking Member Kirsten Gillibrand (D-NY) and Senator Tommy Tuberville (R-AL).

At roughly the 40-minute mark, Senator Tuberville began asking a series of pointed questions, including the one that maps directly onto the problem GKS set out to quantify: "This is not a partisan issue, this is a national security issue... Dr. de la Monte, can you tell me how often unannounced inspections happen at foreign pharma facilities?"

Senator Tommy Tuberville (R-AL) is questioning the witness panel.

Dr. de la Monte noted they are both infrequent and often tipped off in advance. I specifically highlight this exchange because it is one on which GKS was able to build an entire report. Peer-reviewed research shows foreign facilities post-inspection observation rates 1.3 to 1.8 times higher than the U.S. baseline of 49.3% (China 69.0%, India 62.3%), as documented in The Foreign Inspection Gap (Journal of Pharmaceutical Innovation, 2026).

Chairman Scott's full opening statement is linked and attached here:

View Chairman Scott's full opening statement (PDF)

Topics and Reality

Some incredible stories and personal backgrounds were featured here. In no way are my recounts exhaustive or comprehensive. I urge those interested in the following topics to take action directly:

• Drug supply chain security
• How we regulate the 80%+ of U.S. prescriptions that are generic
• Pre-announced foreign inspections vs. surprise inspections at home (a paper George Kwiecinski published on this topic)
• Country-of-origin labeling, your right to know where your meds are made

Progress is already underway, and more is on the table. Some of the changes that have been and are being accomplished, for those interested further:

Recently passed: the FY 2026 NDAA added a pharma supply chain mapping requirement, but it is narrow to DoD/TRICARE, not consumer-facing.

Proposing: the CLEAR LABELS Act (S. 3788) would require Rx labels to name the original makers of finished drugs and APIs, on-label or via barcode/QR to a searchable database. That database clause is your wedge.

Final Remarks and Disclosures

Hearings like this one put names and faces to a problem too often reduced to statistics. The witnesses, the senators, and the data all point to the same conclusion: the systems meant to guarantee drug quality have not kept pace with how globalized our supply has become. That gap, between what we import and what we actually inspect and verify, is exactly where this conversation needs to keep going.

Disclosure: in no way are these comments political, nor do they represent the political stance of GKS. This is a blog published by the author, a GKS publisher at the time of posting, written to cover topics where GKS data has helped support the facts and evidence surrounding this hearing and the witness testimony.

About GKS: Global Key Solutions (GKS) is building the regulatory intelligence layer for post-market quality and compliance, turning audits, inspections, warning letters, recalls, and enforcement signals into real-time, defensible insights for pharma quality and regulatory teams.

See George Kwiecinski's LinkedIn post from the week in D.C..